Back to top

messenger-rna: Archive

Zacks Equity Research

Moderna (MRNA) Beats on Q4 Earnings & Sales, Reiterates View

Moderna (MRNA) beats expectations for earnings and sales. Management reiterates guidance to record around $4 billion from product sales in 2024.

MRKPositive Net Change MRNAPositive Net Change ACETPositive Net Change PBYIPositive Net Change

Zacks Equity Research

Moderna (MRNA) Gears Up for Q4 Earnings: Will It Top Estimates?

Investors' focus will likely be on updates on Moderna's (MRNA) pipeline, especially its late-stage pipeline candidates, when it reports fourth-quarter earnings.

MRKPositive Net Change MRNAPositive Net Change ARQTNegative Net Change CGEMNegative Net Change